Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study-Reference-Cited by-同舟云学术

Vedolizumab does not increase risk of clostridium difficile infection in patients with inflammatory bowel disease using vedolizumab: A retrospective cohort study

Published:2023-09 Issue:9 Volume:31 Page:101736
ISSN:1319-0164
Container-title:Saudi Pharmaceutical Journal
language:en
Short-container-title:Saudi Pharmaceutical Journal

Author:

Saad Alshahrani Abdulaziz,Mohammad Danah,attieh Alzahrani Mohammad,Narula Neeraj

Publisher

Elsevier BV

Subject

Pharmaceutical Science,Pharmacology

Reference25 articles.

1. Excess hospitalization burden associated with clostridium difficile in patients with inflammatory bowel disease;Ananthakrishnan;Gut,2008

2. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia;Bartlett;N. Engl. J. Med.,1978

3. Risk factors for clostridium difficile infection;Bignardi;J. Hosp. Infect.,1998

4. Centers for Disease Control and Prevention (CDC), 2005. Severe clostridium difficile-associated disease in populations previously at low risk – four states. MMWR Morb. Mortal Wkly. Rep. 54, 1201–1205.

5. Management of inflammatory bowel disease with clostridium difficile infection;D’Aoust;World J. Gastroenterol.,2017

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association between vedolizumab and risk of clostridium difficile infection in patients with ulcerative colitis: A systematic review and meta-analysis;Saudi Journal of Gastroenterology;2024-06-07

2. Mesalazine/vedolizumab;Reactions Weekly;2024-03-16

3. Topical issues of therapy for patients with ulcerative colitis;Meditsinskiy sovet = Medical Council;2024-01-19